PHARMAC funding of 9-week concurrent trastuzumab (Herceptin) for HER2-positive early breast cancer

New Zealand Medical Journal

Volumn 120, Issue 1256, 2007, Pages

  Metcalfe, Scott ^a   Evans, Jackie ^a   Priest, Ginny ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CARBOPLATIN; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; NAVELBINE; PACLITAXEL; PLACEBO; TAXANE DERIVATIVE; TRASTUZUMAB; ANTINEOPLASTIC AGENT; BRIDGED COMPOUND; MONOCLONAL ANTIBODY; TAXANE; TAXOID; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ARTICLE; BREAST CANCER; BUDGET; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DISEASE FREE SURVIVAL; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFICACY; EARLY CANCER; EVIDENCE BASED MEDICINE; FOLLOW UP; HEALTH CARE FINANCING; HEALTH SERVICE; HUMAN; MEDICAL DECISION MAKING; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEW ZEALAND; OUTCOMES RESEARCH; QUALITY ADJUSTED LIFE YEAR; RELIABILITY; RESOURCE MANAGEMENT; RISK BENEFIT ANALYSIS; SAMPLE SIZE; STATISTICAL SIGNIFICANCE; VALIDITY; ADJUVANT CHEMOTHERAPY; ADULT; BREAST TUMOR; CONTROLLED CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG INDUSTRY; ECONOMICS; FEMALE; FINANCIAL MANAGEMENT; GENETICS; MIDDLE AGED; MORTALITY; PROPORTIONAL HAZARDS MODEL; PROTO ONCOGENE; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK ASSESSMENT; SURVIVAL; TIME;

ADULT; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; BRIDGED COMPOUNDS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG INDUSTRY; FEMALE; FINANCIAL MANAGEMENT; FOLLOW-UP STUDIES; GENES, ERBB-2; HUMANS; MIDDLE AGED; NEW ZEALAND; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS; RISK ASSESSMENT; SURVIVAL ANALYSIS; TAXOIDS; TIME FACTORS;

EID: 34447622853     PISSN: None     EISSN: 11758716     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Rosevear M. PHARMAC and Herceptin for early-stage breast cancer in New Zealand: Herceptin or deception? N Z Med J. 2006 Jun 2; 119(1235):U2014. http://www.nzma.org.nz/joumal/l19-1235/2014/
2. Petersen S, Rosevear M. Roche responds to the 'Herceptin or deception' article-and response by the article's author. N Z Med J. 2006 Jul 7; 119(1237):U2069. http://www.nzma.org.nz/journal/119-1237/2069/
3. Burgess E, Rosevear M. Breast Cancer Advocacy Coalition responds to the 'Herceptin or deception' article-and response by the article's author. N Z Med J. 2006 Jul 7;119(1237):U2065. http://www.nzma.org.nz/journal/ 119-1237/2065/
4. New Zealand datasheet (Medsafe): Herceptin® Trastuzumab 150 mg and 440 mg powder fo concentrate for solution for infusion, http://www.medsafe.govt.nz/profs/Datasheet/h/Herceptininf.htm
5. Piccart-Gebhart M.J. Procter M, Leyland-Jones B, et al. Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer. N EngI J Med 2005;353(16):1659-1672. http://content.nejm.org/cgi/content/full/353/ 16/1659
6. Belgian Health Care Knowledge Centre (KCE). Trastuzumab in early stage bfeast cancer. KCE reports vol. 34C, 2006. http://kce.fgov.be/index/ en.aspx?ID=O&SGREF=5211&CREF=7198
7. Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, et al. 2 year follow up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: A randomised controlled trial. Lancet 2007;369:29-36. http://www.thelancet.com/journals/lancet/article/ PIISO140673607600282/fulltext
8. Romond, EH, Perez EA, Bryant J, et al. Trastuzumab plus Adjuvant Chemotherapy for Operable HER-2 positive breast cancer. N EngI J Med 2005;353(16):1659-1672. http://content.nejm.orp-/cgi/content/full/353/ 16/1673
9. Supplemental Figure 1 in the on-line Supplementary Appendix to Romond et al NEJM 2005, available at http)://content.nejm.org-/cgi/content/full/ 353/16/1673/DCI.
10. Perez EA. Further Analysis of NCCTC-N9831. Slide presentation ASCO annual meeting 2005, available online at http://www.asco.org/ac/ 1,1003,12-002511-0018-0034-0019-005815-0021-001,00.asp
11. Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, et al, on behalf of the BCIRG 006 Investigators. Phase III Trial Comparing AC-T with AC-TH and with TCH in the Adjuvant Treatment of HER2 positive Early Breast Cancer Patients: Second Interim Efficacy Analysis. Slide presentation ASCO annual meeting 2006, available online at http://www.bcirg.orp-/NR/rdonlyres/ eqkdodg2dy7t557o7s6uvj7ytpe6gcfg5gzmh2ely6hnhh5pjla bz3nd6jddlnao7qoikej3edohsijyiisfvp367uuc/BCIRG 006+2nd+Interim+Analysis.pd
12. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, Alanko T, Kataja V, et al; FinHer Study Investigators. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med. 2006;354(8):809-20. http://content.nejm.org/cgi/content/full/354/8/809
13. Schulz K F. Assessing allocation concealment and blinding in randomised controlled trials. Why bother? Evidence Based Medicine 2000; 5:36-37.
14. Jackson R, Ameratunga S, Broad J, Connor J, Lethaby A, Robb G, Wells S, Glasziou P, Heneghan C. The GATE frame: Critical appraisal with pictures. Evid Based Med. 2006 Apr;l 1(2):35-8. http://ebm.bmj.com/ cgi/content/full/11/2/35.
15. S Wells. Summary of GATE critical appraisals of trastuzumab trials. EPIQ, University of Auckland, May 2007.
16. New Zealand Public Health and Disability Act 2000, Section 49 Pharmac to consult in implementing objectives and carrying out functions.
17. PHARMAC. Operating policies and procedures of the Pharmaceutical Management Agency ("PHARMAC"), 2nd edition. January 2001. http://www.pharmac.govt.nz/pdf/opps.pdf. sections 3.3.3 and 4.2.
18. Sledge GW, O'Niell A, Thor AD, Kahanic SP, Zander SP, Davidson NE. Adjuvant trastuzumab: Long term results of E2198. Poster presentation 2075, SABCS 2006. http://www.abstracts2view.com/sabcs06/ view.php?nu=SABCS06L_561
19. Pegram MD, Lopez A, Konecny G, Slamon DJ. Trastuzumab and chemotherapeutics: Drug interactions and synergies. Semin Oncol. 2000;27(6 Suppl 11):21-5
20. Jahanzeb M. Trastuzumab-based combinations in metastatic breast cancer: how to make a choice. Clin Breast Cancer. 2003 Apr;4(1):28-38.
21. PHARMAC. TAR 75 Trastuzumab (Herceptin) in HER-2 positive early breast cancer with 9 week regimen CUA. Released May 2007. http://www.pharmac.govt.nz/pdf/030307c.pdf
22. Medsafe. Regulatory issues - unapproved use of medicines. http://www.medsafe.govt.nz/Profs/RIss/unapp.asp
23. Gazarian M, Kelly M, McPhee JR, Graudins LV, Ward RL, Campbell TJ. Off-label use of medicines: Consensus recommendations for evaluating appropriateness. Med J Aust. 2006 Nov 20;185(10):544-8. http://www.mja.com.au/public/issues/185_10_201106/ gaz10250_fm.html
24. Australian datasheet: HERCEPTIN® PRODUCT INFORMATION, dated 21 April 2006. http://www.pbs.gov.au/pi/ropherce10406.pdf
25. Herceptin and early breast cancer: A moment for caution. Lancet 2005 Nov 12;366(9498):1673. http://www.thelancet.com/journals/lancet/article/ PIIS0140673605676702/fulltext
26. Ward S, Pilgrim H, Hind D. Trastuzumab for the treatment of primary breast cancer in HER2 positive women: A Single Technology Appraisal. University of Sheffield School of Health and Related Research (ScHARR), May 2006. http://www.nice.org.uk/page.aspx?o=328487
27. Hind D, Pilgrim H, Ward S. Questions about adjuvant trastuzumab still remain. Lancet 2007; 369:3-5. http://www.thelancet.com/journals/ lancet/article/PIIS014067360760004X/fulltext
28. PHARMAC media release 16 February 2007. Herceptin: Significant doubts remain over 12-month treatment http://www.pharmac.govt.nz/pdf/ 160207a.pdf
29. Metcalfe RS, Crausaz C, Evans J, Brougham M. Dealing with opportunity cost - a New Zealand perspective on trastuzumab funding. Rapid response posted on bmj.com 11 May 2007 http://www.bmj.com/cgi/content/full/334/ 7600/936, responding to Wells, J, Cheong-Leen C. NICE appraisals should be everyone's business, BMJ 2007; 334:936-938 http://www.bmj.com/cgi/content/full/334/7600/936
30. US datasheet: Initial US Approval: September 1998, Revision Date: November 2006. http://www.gene.com/gene/products/information/oncolog/ herceptin/insert.jsp
31. Brougham M, Metcalfe S, McNee W. Our Advice? Get a budget! HealthCare Papers 2002;3:83-6. http://www.longwoods.com/hp/3-1DrugPolicy/ HP31DrugRPolicy.pdf
32. Wells J, Cheong-Leen C. NICE appraisals should be everyone's business. BMJ 2007; 334:936-938 http://www.bmj.com/cgi/content/ful/334/600/ 936
33. Barrett A, Roques T, Small M, Smith RD. How much will Herceptin really cost? BMJ. 2006 Nov 25;333(7578):1118-20. http://www.bmj.com/cgi/ content/full/333/7578/1118
34. Wells J, Cheong-Leen C. NICE appraisals should be everyone's, business, BMJ 2007; 334:936-938 http://www.bmj.com/cgi/content/full/334/7600/ 936
35. Simoens S. Economic evaluation and decision making: Reimbursing trastuzumab in early-stage breast cancer. Pharmacoeconomics. 2007;25(3):181-5.
36. Grocott R, Metcalfe S. Going against the flow: The impact of PHARMAC not funding COX-2 inhibitors for chronic arthritis. N Z Med J. 2005 Oct 7;118(1223):U1690. http://www.nzma.org.nz/journal/118-1223/1690/
37. Robson B, Purdie G, Cormack D. 2006. Unequal Impact: Mäori and Non-Mäori Cancer Statistics. 1996-2001. Wellington: Ministry of Health. http://www.moh.govt.nz/moh.nsf/pagesmh/4761/$File/ unegual-impact-maori-nonmaori-cancer-statistics-96-01.pdf
38. PHARMAC media release 16 February 2007. PHARMAC supporting international trial and continuing assessment of funding options. http://www.pharmac.govt.nz/pdf/160207.pdf